G-CSF
DrugOther names: Filgrastim, Neupogen, Granulocyte Colony-Stimulating Factor, Recombinant Methionyl Human G-CSF
NCT Number: NCT01331590
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Early Phase 1
University of Chicago Medical Center, Chicago, Illinois, United States
In this study, we will combine G-CSF as priming prior to and during the administration of salvage chemotherapy regimen in ALL. Abundant data suggests that leukemic cells receive key growth and survival signals from the bone marrow microenvironment. Our preclinical data show that 4-5 days of G-CSF treatment is associated with a loss of osteoblasts and decreases expression of key chemokine/ cytokines which support lymphocyte development. The investigators hypothesize that G-CSF will disrupt the protective effects of the bone marrow microenvironment and augment the effect of chemotherapy in adults with ALL. This is a pilot study of G-CSF priming in adult patients with relapsed or refractory ALL to determine the feasibility and to characterize the effect of G-CSF treatment on the marrow microenvironment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Filgrastim, Neupogen, Granulocyte Colony-Stimulating Factor, Recombinant Methionyl Human G-CSF
Other names: Ifex, Isophosphamide
Other names: Etopophos, VP-16
Other names: Decadron
Other names: Mesnex
Time frame: 30 days after start of treatment
Time frame: Day 46 of treatment
Defined as neutrophil recovery (ANC > 1,000/mm3) > 42 days after the start of chemotherapy in the absence of persistent leukemia
Time frame: 42 days
Time frame: 2 years
Every 6 months
Time frame: 2 years
Every 6 months
Time frame: 2 years
Every 6 months
Time frame: 30 days post treatment
Time frame: Baseline
Morphology, cytogenetics, immunophenotype, WBC, and performance status
Washington University School of Medicine
Other
A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03384654
Hematologic Diseases, Hemic and Lymphatic Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT01386619
Bone Marrow Diseases, Hematologic Diseases
Frankfurt, Germany
View Trial DetailsNCT04456959
Hematologic Diseases, Hemic and Lymphatic Diseases
Bristol, United Kingdom
View Trial DetailsNCT03545659
Disease Attributes, Hematologic Diseases
Aarhus N, Denmark
View Trial Details